Beijing Hotgen Biotech Co Ltd
SSE:688068
Beijing Hotgen Biotech Co Ltd
Cost of Revenue
Beijing Hotgen Biotech Co Ltd
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Beijing Hotgen Biotech Co Ltd
SSE:688068
|
Cost of Revenue
-¥209.9m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
N/A
|
|
WuXi AppTec Co Ltd
SSE:603259
|
Cost of Revenue
-¥23.6B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
Cost of Revenue
-¥7.6B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
Cost of Revenue
-¥10.2B
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
Cost of Revenue
-¥4.5B
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-36%
|
|
Genscript Biotech Corp
HKEX:1548
|
Cost of Revenue
-$430m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
N/A
|
See Also
What is Beijing Hotgen Biotech Co Ltd's Cost of Revenue?
Cost of Revenue
-209.9m
CNY
Based on the financial report for Dec 31, 2023, Beijing Hotgen Biotech Co Ltd's Cost of Revenue amounts to -209.9m CNY.
What is Beijing Hotgen Biotech Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-34%
Over the last year, the Cost of Revenue growth was 88%. The average annual Cost of Revenue growth rates for Beijing Hotgen Biotech Co Ltd have been -3% over the past three years , -34% over the past five years .